Todos os estudos
RecrutamentoFASE1, FASE2INTERVENCIONISTA

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

This research study is looking into a new medicine, pirtobrutinib, for adults with Immune Thrombocytopenia (ITP). ITP is a condition where your immune system mistakenly attacks and destroys platelets, which are tiny blood cells that help your blood clot. The study has two main parts. The first part will check how well people tolerate pirtobrutinib and look for any unwanted side effects. The second part will compare different doses of pirtobrutinib against a dummy pill (placebo) to see how effective it is in increasing platelet counts and if it's safe. Taking part involves taking the study medicine by mouth and having regular blood tests.

Em resumo

Status
Recrutamento
Fase
FASE1, FASE2
Patrocinador
Eli Lilly and Company
Meta de inscrição
68
Iniciar
30 de jul de 2025
Conclusão estimada
01 Feb 2029

Sobre o que é este estudo?

This study is about a new medicine called pirtobrutinib for adults who have a condition called Immune Thrombocytopenia, or ITP. ITP happens when your body's defence system, called the immune system, gets confused and starts attacking your own platelets. Platelets are really important because they help your blood clot and stop bleeding. If you have ITP, your platelet count can be very low, which increases your risk of bruising and bleeding.

The main goal of this study is to find out if pirtobrutinib is a safe and effective treatment for ITP. The study will happen in two stages. First, we need to understand if the medicine is well-tolerated and what kind of side effects it might have. This helps us ensure patient safety. After that, we'll look more closely at whether different amounts (doses) of pirtobrutinib can help increase platelet counts compared to a 'dummy' pill that contains no medicine (a placebo).

If you take part, you'll be given the study medicine, pirtobrutinib, as a tablet to swallow. The researchers will also take blood samples regularly. These blood tests help them understand how much of the medicine gets into your body and how long it stays there. The study will last for different periods depending on which part you are in, but it could be up to about 16 weeks for the first stage or up to 28 weeks for the second stage, not including the initial checks to see if you can join.

Pontos principais

  • This study is testing a new medicine, pirtobrutinib, for adults with ITP.
  • It aims to check the safety and effectiveness of the medicine.
  • Participants will take the medicine as a tablet and have regular blood tests.
  • The study has two parts: one to find the right dose, and another to compare it with a dummy pill.
  • Taking part means frequent clinic visits and medical supervision.
  • Você pode parar de participar a qualquer momento.

Quem pode ser elegível?

To be able to join this study, you would need to be an adult (18 years or older) with a specific type of ITP called 'primary ITP'. This means your low platelet count isn't caused by another known illness. You should also have shown some improvement in your platelet count with at least one previous ITP treatment, even if that treatment no longer works for you now. Importantly, your ITP should have returned or not responded well to treatments, and your platelet count generally needs to be quite low (under 30,000) on a couple of recent occasions.

There are also some reasons why you might not be able to join. For example, if you've had a blood clot in the past year, or if you recently needed a blood transfusion. People with certain severe heart conditions, a history of blood cancers, or certain types of hepatitis (like Hepatitis B or C) would also not be able to take part. The study team will check your overall health, including your liver and kidney function, to make sure it's safe for you to participate.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Have you been diagnosed with primary ITP (ITP not caused by another disease)?
  3. Have you tried at least one ITP treatment before, and it helped at some point?
  4. Is your ITP not responding well to current treatments or has it returned?
  5. Are your platelet counts generally below 30,000?
  6. Do you have suitable liver, kidney, and blood cell function (as determined by tests)?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this study, you will be taking the study medicine, pirtobrutinib, as a tablet by mouth. You will have regular visits to the clinic for medical check-ups, which will include physical exams and several blood tests. These blood tests help the study team monitor your platelet counts, check for any side effects, and see how your body handles the medicine. For women who can get pregnant, there will be rules about using contraception during the study. The total time you would be involved in the study could be up to around 16 weeks for the first part or up to 28 weeks for the second part, plus an initial assessment period.

Riscos e benefícios potenciais

Taking part in a clinical trial may offer potential benefits, such as access to a new treatment before it's widely available, and you would receive very close medical attention from the study team. However, there are also potential risks, including side effects from the study medicine, which the researchers will carefully monitor. The study will also involve regular clinic visits and blood tests, which can be time-consuming. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (43)

  • Centro de Câncer Compreensivo USC Norris
    Código postal verificado
    Los Angeles, Estados Unidos· Recrutamento
  • Universidade de Stanford
    Código postal verificado
    Palo Alto, Estados Unidos· Recrutamento
  • Hospital Universitário MedStar Georgetown
    Código postal verificado
    Washington D.C., Estados Unidos· Recrutamento
  • University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center
    Código postal verificado
    Miami, Estados Unidos· Ainda não recrutando
  • Bleeding and Clotting Disorders Institute
    Código postal verificado
    Peoria, United States· Ainda não recrutando
  • Ochsner Clinic Foundation
    Código postal verificado
    Nova Orleans, Estados Unidos· Recrutamento
  • Clínica Mayo
    Código postal verificado
    Rochester, Estados Unidos· Recrutamento
  • Texas Oncologia - Centro Sul
    Código postal verificado
    Austin, Estados Unidos· Recrutamento
  • Centro de Câncer MD Anderson
    Código postal verificado
    Houston, Estados Unidos· Recrutamento
  • Texas Oncology Gulf Coast
    Código postal verificado
    The Woodlands, United States· Recrutamento
  • Nanfang Hospital of Southern Medical University
    Código postal verificado
    Guangzhou, China· Recrutamento
  • Qilu Hospital of Shandong University
    Código postal verificado
    Jinan, China· Recrutamento

Perguntas frequentes

What is ITP?

ITP stands for Immune Thrombocytopenia. It's a condition where your body's immune system accidentally attacks and destroys your own platelets, which are blood cells that help stop bleeding.

What is pirtobrutinib?

Pirtobrutinib is the new medicine being tested in this study. It's designed to help manage ITP.

What is a 'dummy pill' (placebo)?

A dummy pill, or placebo, looks just like the real medicine but contains no active drug. It helps researchers compare the effects of the actual medicine fairly.

Quanto tempo durará o estudo se eu participar?

The study could last up to about 16 weeks for the first part or up to 28 weeks for the second part, depending on which stage you are in, plus an initial screening period.

Posso parar de participar do estudo se mudar de ideia?

Yes, you can leave the study at any time, for any reason. Your decision will not affect your medical care.

Como saber mais

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study of Pirtobrutinib in Participants With Immune Thrombo…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.